<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2012">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631864</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696B2207</org_study_id>
    <secondary_id>2012-002606-40</secondary_id>
    <nct_id>NCT01631864</nct_id>
  </id_info>
  <brief_title>Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices (BfArM)</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated the effects of LCZ696 on insulin sensitivity, lipolysis, and
      oxidative metabolism in obese hypertensive subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Insulin Sensitivity Index</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The insulin sensitivity index was assessed by hyperinsulinemic euglycemic clamp (HEGC). A positive change from baseline indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Adipose Tissue Lipolysis, Glycerol Concentrations</measure>
    <time_frame>57 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lipolysis was assessed through subcutaneous adipose tissue microdialysis. The actual measure type is adjusted geometric mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative Metabolism</measure>
    <time_frame>57 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Oxidative metabolism was assessed by indirect calorimetry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events, Serious Adverse Events and Deaths</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse event monitoring was conducted throughout the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Hypertension</condition>
  <condition>Concurrent Obesity</condition>
  <arm_group>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696 was provided as 400 mg tablets.</description>
    <arm_group_label>LCZ696</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine</intervention_name>
    <description>amlodipine was provided as 5 mg tablets.</description>
    <arm_group_label>amlodipine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo to LCZ696 and amlodipine.</description>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_label>amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any study assessment is performed.

          -  Males and females of non-childbearing potential ≥ 18 years of age.

          -  Subjects with mild to moderate essential hypertension,

               -  Untreated subjects must have a mean seated SBP (msSBP) ≥ 130 mmHg and &lt; 180 mmHg
                  at screening.

               -  Pre-treated subjects must have a msSBP ≤ 160 mmHg at screening and &lt; 180 mmHg at
                  the end of the washout period.

          -  Waist circumference ≥ 102 cm (men) and ≥ 88 cm (women);

        Exclusion criteria:

          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer; or longer if required by local
             regulations.

          -  History of angioedema, drug-related or otherwise

          -  History of hypersensitivity to LCZ696, amlodipine, or drugs of similar chemical
             classes.

          -  Severe hypertension (grade 3 of WHO classification; msDBP ≥100 mmHg and/or msSBP ≥
             180 mmHg) at screening or at the end of the washout period.

          -  Type 1 or Type 2 diabetes mellitus.

          -  Dyslipidemia requiring pharmacological therapy with a fibrate or nicotinic acid.

          -  Concomitant use of anti-hypertensives, anti-diabetics, or drugs with effects on
             glucose or lipid metabolism for the duration of the study.

        Other protocol defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>5800</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>July 11, 2015</lastchanged_date>
  <firstreceived_date>June 27, 2012</firstreceived_date>
  <firstreceived_results_date>July 11, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension, obesity, insulin sensitivity, lipolysis, LCZ696</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LCZ696</title>
          <description>LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Amlodipine</title>
          <description>amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCZ696</title>
          <description>LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Amlodipine</title>
          <description>amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50"/>
                <measurement group_id="B2" value="48"/>
                <measurement group_id="B3" value="98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.9" spread="9.6"/>
                <measurement group_id="B2" value="50.5" spread="9.4"/>
                <measurement group_id="B3" value="51.2" spread="9.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="41"/>
                <measurement group_id="B2" value="35"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Insulin Sensitivity Index</title>
        <description>The insulin sensitivity index was assessed by hyperinsulinemic euglycemic clamp (HEGC). A positive change from baseline indicates improvement.</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic Analysis Set (PDS): Only participants from the PDS, who had both baseline and day 56 values, were included in the analysis. The PDS included all randomized participants who received at least one dose of study drug and had no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Insulin Sensitivity Index</title>
            <description>The insulin sensitivity index was assessed by hyperinsulinemic euglycemic clamp (HEGC). A positive change from baseline indicates improvement.</description>
            <units>ug/kg*min/(mmol/L*pmol/L)</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.192" lower_limit="0.025" upper_limit="0.359"/>
                  <measurement group_id="O2" value="0.065" lower_limit="-0.0116" upper_limit="0.246"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Local Adipose Tissue Lipolysis, Glycerol Concentrations</title>
        <description>Lipolysis was assessed through subcutaneous adipose tissue microdialysis. The actual measure type is adjusted geometric mean.</description>
        <time_frame>57 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic Analysis Set (PDS): Only participants from the PDS, who had both baseline and day 56 values, were included in the analysis. The PDS included all randomized participants who received at least one dose of study drug and had no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="42"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Local Adipose Tissue Lipolysis, Glycerol Concentrations</title>
            <description>Lipolysis was assessed through subcutaneous adipose tissue microdialysis. The actual measure type is adjusted geometric mean.</description>
            <units>micro mol/L</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="82.46" lower_limit="74.53" upper_limit="91.23"/>
                  <measurement group_id="O2" value="65.91" lower_limit="59.22" upper_limit="73.37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxidative Metabolism</title>
        <description>Oxidative metabolism was assessed by indirect calorimetry.</description>
        <time_frame>57 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Pharmacodynamic Analysis Set (PDS): Only participants from the PDS, who had both baseline and day 56 values, were included in the analysis. The PDS included all randomized participants who received at least one dose of study drug and had no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="46"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Oxidative Metabolism</title>
            <description>Oxidative metabolism was assessed by indirect calorimetry.</description>
            <units>carbon dioxide to oxygen ratio</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.787" lower_limit="0.760" upper_limit="0.814"/>
                  <measurement group_id="O2" value="0.775" lower_limit="0.746" upper_limit="0.804"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events, Serious Adverse Events and Deaths</title>
        <description>Adverse event monitoring was conducted throughout the study.</description>
        <time_frame>8 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety Analysis Set (SAS): The SAS included all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696</title>
            <description>LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Amlodipine</title>
            <description>amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adverse Events, Serious Adverse Events and Deaths</title>
            <description>Adverse event monitoring was conducted throughout the study.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Adverse events (serious and non-serious)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serious adverse events</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Deaths</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ696</title>
          <description>LCZ696 400 mg plus placebo to Amlodipine once daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Amlodipine</title>
          <description>Amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>RUPTURED CEREBRAL ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
